Merck (NYSE:MRK)
On Monday, Guggenheim raised its rating on Merck (NYSE:MRK), moving it from Neutral to Buy and highlighted the firm’s essential medicines, such as Keytruda, Gardasil, and Januvia, to anticipate that the company would outperform the consensus estimate in 2023. The company has a target price of $104 per share for Merck stock.
The research group that Seamus Fernandez heads notes that it “would be a substantial value-enhancing event” if a cancer therapy combination comprising of Keytruda and anti-TIGIT chemical vibostolimab successfully treated the disease. Analysts believe this might prolong the option for immune-oncology treatment with Keytruda in patients with PDL1+ cancer “far beyond 2030.”
The analysts underlined management remarks on expansions to the Human Papillomavirus vaccine Gardasil supply, with new bulk manufacturing facilities being online in the middle of 2023, which would maintain a growth trajectory through the decade.
“We believe there is a potential upside to sotatercept if the STELLAR trial succeeds this quarter,” Guggenheim noted, citing a late-stage trial for treating pulmonary arterial hypertension, which Merck stock said met today’s primary goal. “We believe there is a potential upside to sotatercept if the STELLAR trial succeeds this quarter,” Guggenheim noted.
As a result of a recent court judgment that went against Viatris (VTRS) in a patent battle, the team estimates that the exclusivity period for the diabetes drug Januvia will extend beyond 2023. The result of this is the sales projections for Januvia.
Meta Description
Guggenheim upgraded Merck stock to Buy, citing profits outperformance to come.
Featured Image – Megapixl © Wellesenterprises
Author Shariq Khan 
